Telo Genomics Retains Former Abbott & Siemens Veteran Gregg Mayer to Lead the Development of the Company’s Industry Partnership Strategy
03 févr. 2021 08h55 HE
|
Telo Genomics Corp.
TORONTO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that the Company has entered into a consulting agreement with the...
Telo Genomics Presents at ASH 2020 The Results of Hodgkin’s Lymphoma Clinical Study
09 déc. 2020 09h00 HE
|
Telo Genomics Corp.
TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that the Company has presented the results of its Hodgkin’s lymphoma...
Telo Genomics Announces Study Results Showing That TeloView® Differentiates Between Stable Smoldering Multiple Myeloma Patients and Patients That Progressed to Active Multiple Myeloma
16 nov. 2020 11h13 HE
|
Telo Genomics Corp.
TORONTO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce the positive results of its smoldering multiple myeloma proof of concept...
Telo Genomics Announces the Final Assignment of Patents on Hematological Cancers, Liquid Biopsy and Alzheimer’s Disease
11 nov. 2020 12h26 HE
|
Telo Genomics Corp.
TORONTO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that it has received final approval and grant of three of its pending...
Telo Genomics Announces Warrant Exercise Agreement
21 oct. 2020 08h30 HE
|
Telo Genomics Corp.
TORONTO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (OTC: TDSGF) (the “Company” or “TELO”) is pleased to announce that it has engaged Leede Jones Gable Inc. and Mackie...
Telo Genomics Announces that Positive Results of Smoldering Multiple Myeloma Study Selected for Online Publication Within ASH 2020 Proceedings
13 oct. 2020 09h15 HE
|
Telo Genomics Corp.
TORONTO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that its abstract submitted to the American Society of Hematology (ASH)...
Telo Genomics Launches a Commercial Evaluation of Applied Spectral Imaging Automation (AI) with TELO Workflow
14 sept. 2020 09h15 HE
|
Telo Genomics Corp.
TORONTO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that it has launched a commercial evaluation in collaboration with...
Telo Genomics announces Multiple Myeloma collaboration with Mayo Clinic
20 déc. 2019 09h00 HE
|
Telo Genomics Corp.
TORONTO, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”), is pleased to announce that it has signed a collaboration agreement with Mayo Clinic in...
Telo Genomics Announces Grant of Stock Options
28 nov. 2019 08h45 HE
|
Telo Genomics Corp.
TORONTO, Nov. 28, 2019 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) announces that it has granted incentive stock options to various directors, officers, employees...
Telo Genomics Completes Oversubscribed $1.735 Million Financing, Debt Settlement and Share Consolidation
25 nov. 2019 08h45 HE
|
Telo Genomics Corp.
TORONTO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that it has closed its previously announced oversubscribed $1,735,500...